Imbruvica for Non-Oncology Uses
Customize your policy alerts
Sign up for Cigna Policy IP0320 alerts
Get alerted when Policy IP0320 changes without checking for updates manually.
Monitor payer policy activity
Defines Cigna's prior authorization and medical necessity criteria for coverage of Imbruvica when used for non-oncology indications, primarily chronic graft-versus-host disease, and applies to Cigna-administered health benefit plans.
Graft-Versus-Host Disease, Chronic: The requirement that the patient has tried at least 'one conventional systemic treatment' was reworded to 'one systemic medication for graft-versus-host disease' and multiple agents were added to the examples list.
Added statement that certain indications/approval conditions delegated to EviCore by Evernorth will follow the Oncology Medications (1403) coverage policy for prior authorization medical necessity criteria.
Policy title updated from 'Ibrutinib for Non-Oncology Uses' (and earlier 'Oncology - Imbruvica for Non-Oncology Uses') to 'Imbruvica for Non-Oncology Uses'.
Coverage Criteria for Imbruvica (Non-Oncology Uses)
FDA-Approved Indication — Graft-Versus-Host Disease, Chronic
Covered when ALL of the following are met
Examples of systemic medications are listed in the policy (corticosteroids, imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib, belumosudil, axatilimab-csfr, interleukin-2, cyclosporine, tacrolimus, pentostatin, hydroxychloroquine, rituximab, etanercept product).
Imbruvica (ibrutinib) for any non-oncology use other than those explicitly supported by this policy is considered not medically necessary. This policy’s covered non-oncology indication(s) and criteria will be updated if new published data become available.
Use of Imbruvica for non-oncology indications not specifically authorized by this policy (see coverage criteria for chronic graft‑versus‑host disease) is not medically necessary. Providers should consult the policy for the approved non‑oncology indication(s) and any future updates.
Coding and Related Rules
| No codes listed |
Provider Actions, Prior Authorization, and Billing
Prior authorization required
Prior authorization is required for benefit coverage of Imbruvica; approvals are provided for the duration noted in the policy.
Must try ≥1 systemic medication for chronic GVHD before approval
For chronic graft-versus-host disease, the patient must have tried at least one systemic medication for graft‑versus‑host disease (examples listed in the policy) before Imbruvica will be approved.
- Examples include corticosteroids (methylprednisolone, prednisone), imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib, belumosudil, axatilimab-csfr, interleukin-2 (Proleukin), cyclosporine, tacrolimus, pentostatin (Nipent), hydroxychloroquine, rituximab, and an etanercept product.
Use appropriate codes; reimbursement contingent on covered codes
When billing, providers must use the most appropriate codes as of the effective date of the submission; reimbursement is provided only when the requested service is submitted in accordance with the relevant criteria, including covered diagnosis and/or procedure codes.
- Claims billed for conditions or diagnoses not covered under this policy will be denied as not covered.
- Use the appropriate CPT/HCPCS/ICD-10 codes effective on the date of submission.
Denial triggers for unsupported diagnoses/uses
Claims submitted without covered diagnosis or procedure codes under this Coverage Policy will be denied as not covered; use of Imbruvica for any other non-oncology use is considered not medically necessary.
- Denial risk if Imbruvica is billed for non-oncology indications not explicitly supported by this policy (chronic GVHD per criteria).
Definitions
Initial Authorization Criteria
Initial Therapy — Initial authorization criteria for chronic GVHD
Initial authorization criteria for chronic GVHD
Examples of systemic medications provided in policy note (see policy for list including corticosteroids, imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib, belumosudil, axatilimab-csfr, interleukin-2, cyclosporine, tacrolimus, pentostatin, hydroxychloroquine, rituximab, etanercept product).
Continuation Therapy Criteria
Continuation Therapy — Duration of approval for chronic GVHD when criteria are met
Duration of approval for chronic GVHD when criteria are met
Medical director discretion and plan terms apply for subsequent approvals.
Step Therapy Requirements
| Step | Requirement | Notes / Examples |
|---|---|---|
| 1 | Must have tried at least one systemic medication for graft-versus-host disease prior to approval | Examples include corticosteroids (methylprednisolone, prednisone), imatinib, low‑dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib (Jakafi), belumosudil (Rezurock), axatilimab‑csfr (Niktimvo), interleukin‑2 (e.g., Proleukin), cyclosporine, tacrolimus, pentostatin (Nipent), hydroxychloroquine, rituximab, and an etanercept product; policy approves for 1 year when criteria met. |
Site of Care
EviCore‑Delegated Indications Follow Policy 1403
Certain indications and/or approval conditions delegated to EviCore by Evernorth will follow the Oncology Medications (1403) coverage policy for prior authorization medical necessity criteria.
Background
Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor used primarily in oncology and for selected non‑oncology indications. Under this policy, the principal non‑oncology indication addressed is chronic graft‑versus‑host disease (chronic GVHD), for which the drug is FDA‑approved in patients aged ≥ 1 year after failure of one or more lines of systemic therapy. Prior authorization is required for benefit coverage, and approvals for chronic GVHD are provided when all criteria are met (including age and prior systemic therapy) for a duration of 1 year.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.